|
|
Post by u1682002 on Nov 22, 2016 11:47:54 GMT -5
My little theory is that many current Afrezza prescribing doctors on the list are watching MNKD stock also. The financial situation of MNKD has made many of them hesitate to prescribe Afrezza to their patients. With the latest quarterly CC from MNKD, more will be encouraged to start prescribing Afrezza again. So I predict we can see >20% NRX improvement this Friday...
I have been wrong with MNKD stock for so many times already, hope this time I am right! 
|
|
|
|
Post by careful2invest on Nov 22, 2016 11:59:09 GMT -5
My little theory is that many current Afrezza prescribing doctors on the list are watching MNKD stock also. The financial situation of MNKD has made many of them hesitate to prescribe Afrezza to their patients. With the latest quarterly CC from MNKD, more will be encouraged to start prescribing Afrezza again. So I predict we can see >20% NRX improvement this Friday...
I have been wrong with MNKD stock for so many times already, hope this time I am right!
We've all been waiting on a spike in the pps, some of us for many years! May as well throw it out there and see what happens... We're in the dark about many aspects of the goings on of this company, (RLS, dates of applications, etc... Aside from the most recent cc, it has basically been a guessing game for investors. Let's hope your guess is correct... GLTA TRUE LONGS! |
|
|
|
Post by dictatorsaurus on Nov 22, 2016 11:59:25 GMT -5
So Dr's now prescribe drugs depending on the stock price?
I thought I heard it all but you guys have an infinite well of humorous excuses.
|
|
|
|
Post by mannmade on Nov 22, 2016 12:07:35 GMT -5
As pro MannKind and AFREZZA as I am I really doubt any doc is prescribing based on stock price. I also doubt most even know what it is and I doubt that more than a couple, even if that may, have listened to the cc. I do however think that many may have stopped and now perhaps started to prescribe again once they were convinced by their rep that Mnkd is not going away as they may have been led to believe with the termination of the deal with Sanofi.
|
|
|
|
Post by cjm18 on Nov 22, 2016 12:17:39 GMT -5
Reps should have started convincing doctors mannkind was here to stay in july.
|
|
|
|
Post by curiousdoc on Nov 22, 2016 12:33:39 GMT -5
To put this nicely, if you think any doctor who isn't invested in this stock is paying attention to the conference calls of a pharmaceutical company you are delusional...
|
|
|
|
Post by sportsrancho on Nov 22, 2016 12:51:02 GMT -5
My little theory is that many current Afrezza prescribing doctors on the list are watching MNKD stock also. The financial situation of MNKD has made many of them hesitate to prescribe Afrezza to their patients. With the latest quarterly CC from MNKD, more will be encouraged to start prescribing Afrezza again. So I predict we can see >20% NRX improvement this Friday...
I have been wrong with MNKD stock for so many times already, hope this time I am right!
From what I've heard some were made aware of Afrezza for the first time because they saw the headlines when SNY dumped us. So I don't see this as being that far-fetched. |
|
|
|
Post by u1682002 on Nov 22, 2016 13:02:00 GMT -5
As pro MannKind and AFREZZA as I am I really doubt any doc is prescribing based on stock price. I also doubt most even know what it is and I doubt that more than a couple, even if that may, have listened to the cc. I do however think that many may have stopped and now perhaps started to prescribe again once they were convinced by their rep that Mnkd is not going away as they may have been led to believe with the termination of the deal with Sanofi. Well, Somehow I feel the Endos are more human than most of us believe Let's see! |
|
|
|
Post by dg1111 on Nov 22, 2016 13:09:25 GMT -5
My gut feeling after the conference call was that we wouldn't see a dramatic increase in scripts until January. I don't remember the specifics, but Mike made some comments to that effect. He noted waited until then to hire additional sales people. I would be happy to see increases before then, but I am not betting on it.
More relative to the reason cited that we would see an increase this week, I do think that endos would hesitate to prescribe a drug to a new patient if they thought it would be pulled from the market. That said, I doubt that many endos were listening to the conference call. As stated above, it's up to the sales team to convince them that Afrezza will be on the market for the long term.
|
|
|
|
Post by novafett on Nov 22, 2016 14:55:53 GMT -5
So Dr's now prescribe drugs depending on the stock price? I thought I heard it all but you guys have an infinite well of humorous excuses. This... |
|
|
|
Post by silentknight on Nov 22, 2016 15:05:39 GMT -5
While I'd certainly welcome an increase in script numbers, I don't think it's happening anytime soon, not until MNKD re-evaluates its strategy and adjusts to a more effective one or hires more people to carry out the current one. Mike said new hires wouldn't come until January so the soonest I think you see substantial increases would be March or April.
Personally, I'd like to see MNKD do both of those things. People said we'd see increases in August, then September, then October, then November....it's always just around the corner. I think where we are is where we stay unless changes are made.
|
|
|
|
Post by orlon on Nov 22, 2016 15:24:48 GMT -5
All the hope and hype simply boils down to this: No sales in AFREZZA=no profitability=lower PPS. I know Mike/Matt said ads to appear first of 2017, but so far, no ads to date =no pressure on endos to prescribe=no new users=no new sales=no revenue=no rise in PPS. I agree with silentnight, any news is always around the corner. I'll believe the ads when I see them, maybe no in 2017 but 2018, or maybe in the near future...2019. Meanwhile we are back in the loop of...No sales in AFREZZA etc.
|
|
|
|
Post by u1682002 on Nov 22, 2016 15:56:31 GMT -5
All the hope and hype simply boils down to this: No sales in AFREZZA=no profitability=lower PPS. I know Mike/Matt said ads to appear first of 2017, but so far, no ads to date =no pressure on endos to prescribe=no new users=no new sales=no revenue=no rise in PPS. I agree with silentnight, any news is always around the corner. I'll believe the ads when I see them, maybe no in 2017 but 2018, or maybe in the near future...2019. Meanwhile we are back in the loop of...No sales in AFREZZA etc. I share many of your concerns. Nevertheless I backup my gut feeling with another small batch of 5k buy @0.58. Hope it can be paid off in long term even I get wrong again this time. |
|
|
|
Post by falconquest on Nov 22, 2016 17:30:29 GMT -5
All the hope and hype simply boils down to this: No sales in AFREZZA=no profitability=lower PPS. I know Mike/Matt said ads to appear first of 2017, but so far, no ads to date =no pressure on endos to prescribe=no new users=no new sales=no revenue=no rise in PPS. I agree with silentnight, any news is always around the corner. I'll believe the ads when I see them, maybe no in 2017 but 2018, or maybe in the near future...2019. Meanwhile we are back in the loop of...No sales in AFREZZA etc. Bingo! |
|
|
|
Post by slugworth008 on Nov 22, 2016 17:58:12 GMT -5
So Dr's now prescribe drugs depending on the stock price? I thought I heard it all but you guys have an infinite well of humorous excuses. I believe the reference was to MNKD's cash situation and the theory (which I also subscribed to) that some doctor's would be hesitant to prescribe a new drug from a company that was in a precarious financial position. |
|
